

Stem Cells The Holy Grail

14 October 2008 | News



Stem Cells **The Holy Grail**

Patients across the world are holding on to the tenuous thread of life by the hope stem cell therapy provides while the research itself is facing challenges of all kinds—scientific, political, legal and ethical. In this special report BioSpectrum captures what the business leaders are doing to commercialize the research and sustain until we reach the goalpost.

Penetration of Stem Cell Therapy in APAC Region

- Singapore has the highest penetration for stem cell therapy, achieving almost 25% penetration rate by 2010.
- Both Thailand & Taiwan have similar penetration rates achieving overall penetration of almost 4% by 2010.
- Malaysia on the other hand has a relatively lower penetration rate at 1.2% by 2010.
- India offers penetration of 5% by 2010 largely accounted by stem cell therapies derived out of cord blood banking. It has three international players already creating a headstart.
- In the APAC regions, Singapore has the highest penetration with a CAGR of almost 66% for market penetration over the next five years. Malaysia leads second with a CAGR of 33%. Taiwan & Thailand lead on the basis of sheer numbers, but would have a comparatively lower demand trajectory due to restrictive healthcare policies. Source: Stempeutics

Narayan Kulkarni & Sanjeev Jain